Hims Hers Health is trading at $24.79, down 4.66%, with no confirmed company-specific catalyst identified for the November 9 decline. - Q3 results are scheduled after market close and have not yet been reported. - On November 6, Eli Lilly agreed to let Hims Hers Health offer Zepbound and Foundayo through its platform; reports linked the deal to Friday’s gains, not Monday’s drop. - Major indexes were up, so broad-market weakness does not explain the move.